Lilly and Cipla tie up to broaden access of weight-loss therapy | India News
Eli Lilly and Cipla announced an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak. This strategic agreement aims to expand the availability of tirzepatide by enabling broader access across the country beyond cities where Lilly already has an established presence. In March, Lilly launched its blockbuster weight-loss therapy, tirzepatide in India under the brand name Mounjaro. Lilly will manufacture and supply Yurpeak to Cipla, and the price will be the same as Mounjaro, a joint statement said.The average monthly cost of Mounjaro starts around Rs 14 k, and goes up to Rs 27 k per month, depending upon the prescription. Yurpeak will be available in the KwikPenpresentation, a multi-dose single-patient-use prefilled pen. Each pen contains four fixed doses, administered once weekly. The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg. “The introduction of a second brand of tirzepatide in India through our commercial agreement with Cipla furthers Lilly’s commitment to expanding access to innovative treatments for chronic conditions,” said Winselow Tucker, President and General Manager, Lilly India.“ With India facing a growing burden of type 2 diabetes and obesity, broader availability of tirzepatide will ensure that more patients can benefit from this innovative therapy”, he added.
